Impax Asset Management Group plc trimmed its holdings in shares of OmniAb, Inc. (NASDAQ:OABI - Free Report) by 26.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 848,184 shares of the company's stock after selling 300,000 shares during the period. Impax Asset Management Group plc owned approximately 0.73% of OmniAb worth $5,233,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC acquired a new position in shares of OmniAb in the 4th quarter valued at about $546,000. Mirae Asset Global Investments Co. Ltd. increased its stake in OmniAb by 8.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,903 shares of the company's stock valued at $234,000 after buying an additional 2,902 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in OmniAb in the 4th quarter worth approximately $83,000. SG Americas Securities LLC lifted its position in OmniAb by 97.7% in the 4th quarter. SG Americas Securities LLC now owns 53,732 shares of the company's stock worth $332,000 after buying an additional 26,552 shares in the last quarter. Finally, Woodstock Corp boosted its stake in shares of OmniAb by 8.3% during the 4th quarter. Woodstock Corp now owns 743,002 shares of the company's stock valued at $4,584,000 after buying an additional 57,212 shares during the period. 72.08% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
OABI has been the topic of a number of research reports. Truist Financial reaffirmed a "buy" rating and issued a $10.00 price target on shares of OmniAb in a research note on Tuesday, March 26th. Royal Bank of Canada reissued an "outperform" rating and issued a $7.00 target price on shares of OmniAb in a research report on Thursday, March 21st. HC Wainwright reaffirmed a "buy" rating and issued a $11.00 price objective on shares of OmniAb in a research note on Thursday, March 21st. Finally, Benchmark reiterated a "buy" rating and issued a $8.00 price objective on shares of OmniAb in a report on Friday, March 22nd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $9.20.
Check Out Our Latest Stock Report on OABI
OmniAb Stock Down 1.0 %
Shares of NASDAQ:OABI traded down $0.05 during trading on Thursday, reaching $5.20. The stock had a trading volume of 333,061 shares, compared to its average volume of 448,929. The stock has a fifty day simple moving average of $5.49 and a two-hundred day simple moving average of $5.34. OmniAb, Inc. has a 52 week low of $3.14 and a 52 week high of $6.72. The firm has a market capitalization of $609.08 million, a price-to-earnings ratio of -10.16 and a beta of -0.18.
Insider Buying and Selling
In other news, CEO Matthew W. Foehr purchased 225,000 shares of the firm's stock in a transaction on Friday, March 22nd. The stock was bought at an average cost of $5.19 per share, for a total transaction of $1,167,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,908,803 shares of the company's stock, valued at $15,096,687.57. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CFO Kurt A. Gustafson sold 6,954 shares of the business's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $5.27, for a total transaction of $36,647.58. Following the transaction, the chief financial officer now owns 176,697 shares of the company's stock, valued at $931,193.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew W. Foehr bought 225,000 shares of the business's stock in a transaction that occurred on Friday, March 22nd. The shares were bought at an average price of $5.19 per share, with a total value of $1,167,750.00. Following the completion of the purchase, the chief executive officer now owns 2,908,803 shares in the company, valued at $15,096,687.57. The disclosure for this purchase can be found here. Insiders own 7.00% of the company's stock.
OmniAb Company Profile
(
Free Report)
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
See Also
Before you consider OmniAb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.
While OmniAb currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
